Longfei Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Longfei Wu has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Qingfeng Ma
Department of Neurology, Xuanwu Hospital, Capital Medical University
3 shared publications- Wenbo Zhao
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
3 shared publications Xunming Ji
Department of Neurology, Xuanwu Hospital, Capital Medical University
3 shared publicationsJing Wang
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China
2 shared publicationsSijie Li
Neurocardiology Center, Xuanwu Hospital, Capital Medical University, Beijing, China
2 shared publicationsChuanhui Li
Department of Neurology, XuanWu Hospital Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 15 April 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1750720
Urokinase for thrombolysis in patients with acute ischemic stroke: rationale and design of a phase I dose-escalation study
Background: Previous evidence supports the efficacy and safety of intravenous urokinase thrombolysis in acute ischemic stroke (AIS), with additional advantages in terms of cost-effectiveness. Existing studies suggest that treatment response may be dose-dependent; however, current dosing practices remain largely empirical and lack standardization based on high-quality evidence. Establishing a weight-based dosing regimen is, therefore, essential to maximize therapeutic benefit and minimize risks. Objective: To determine the maximum tolerated dose (MTD) of urokinase and to develop an optimized weight-adjusted dosing protocol for AIS. Methods: OUTSET is a prospective, single-center, phase I, dose-escalation clinical trial using a weight-based, rolling-six design in patients with AIS. Patients who meet the inclusion criteria will be assigned to one of four dose groups (15,000 IU/kg, 20,000 IU/kg, 25,000 IU/kg and 30,000 IU/kg). Urokinase will be administered intravenously, diluted in 100 mL of normal saline, over a period of 30 min. Outcomes: The primary endpoint is the identification of the MTD based on dose-limiting toxicity events, including symptomatic intracranial hemorrhage, major bleeding, and other significant adverse events. Discussion: This study offers a structured, weight-based approach to determining the MTD of intravenous urokinase for AIS using a rolling-six dose-escalation design. By addressing the current lack of standardized, body-weight–adjusted dosing protocols, the findings may enhance the clinical safety and efficacy of urokinase thrombolysis. The results are expected to inform future phase II/III trials and support the development of individualized thrombolytic strategies in routine stroke care. Clinical trial registration: ClinicalTrials.gov identifier: NCT07047326.
- 15 April 2026
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1750720
Open AccessUrokinase for thrombolysis in patients with acute ischemic stroke: rationale and design of a phase I dose-escalation study
Background: Previous evidence supports the efficacy and safety of intravenous urokinase thrombolysis in acute ischemic stroke (AIS), with additional advantages in terms of cost-effectiveness. Existing studies suggest that treatment response may be dose-dependent; however, current dosing practices remain largely empirical and lack standardization based on high-quality evidence. Establishing a weight-based dosing regimen is, therefore, essential to maximize therapeutic benefit and minimize risks. Objective: To determine the maximum tolerated dose (MTD) of urokinase and to develop an optimized weight-adjusted dosing protocol for AIS. Methods: OUTSET is a prospective, single-center, phase I, dose-escalation clinical trial using a weight-based, rolling-six design in patients with AIS. Patients who meet the inclusion criteria will be assigned to one of four dose groups (15,000 IU/kg, 20,000 IU/kg, 25,000 IU/kg and 30,000 IU/kg). Urokinase will be administered intravenously, diluted in 100 mL of normal saline, over a period of 30 min. Outcomes: The primary endpoint is the identification of the MTD based on dose-limiting toxicity events, including symptomatic intracranial hemorrhage, major bleeding, and other significant adverse events. Discussion: This study offers a structured, weight-based approach to determining the MTD of intravenous urokinase for AIS using a rolling-six dose-escalation design. By addressing the current lack of standardized, body-weight–adjusted dosing protocols, the findings may enhance the clinical safety and efficacy of urokinase thrombolysis. The results are expected to inform future phase II/III trials and support the development of individualized thrombolytic strategies in routine stroke care. Clinical trial registration: ClinicalTrials.gov identifier: NCT07047326.
- 2 February 2026
- Published by Springer Nature in CNS Drugs
- Vol. 40 (4) , 497-508
Optimizing Early Antithrombotic Therapy Within 24 Hours of Intravenous Thrombolysis in Acute Ischemic Stroke
Early reocclusion is a significant contributor to early neurological deterioration and adverse outcomes in patients with acute ischemic stroke treated with intravenous thrombolysis (IVT) therapy. Although current guidelines recommend delaying antithrombotic therapy until 24 h after IVT to reduce hemorrhagic risks, the persistently high incidence of reocclusion has prompted the exploration of earlier antithrombotic strategies. Despite theoretical benefits, extensive research has not consistently demonstrated the efficacy of early antithrombotic interventions. Nevertheless, a recent randomized controlled trial encouragingly demonstrated that ultra-early intravenous administration of the antiplatelet agent tirofiban after IVT was effective at improving functional outcomes in non-cardioembolic stroke patients with a low risk of hemorrhage. However, the considerable heterogeneity in both antithrombotic regimens and patient populations across existing studies has obscured the identification of beneficial candidates and intervention protocols for early post-thrombolysis antithrombotic therapy. We synthesizes the current evidence regarding patient selection, drug choice, and optimal timing for early antithrombotic therapy, to explore potential improvements in post-IVT antithrombotic management, emphasizing the critical need to balance the prevention of ischemic progression with the risk of hemorrhagic transformation.
- 2 February 2026
- Published by Springer Nature in CNS Drugs
- Vol. 40 (4) , 497-508
Optimizing Early Antithrombotic Therapy Within 24 Hours of Intravenous Thrombolysis in Acute Ischemic Stroke
Early reocclusion is a significant contributor to early neurological deterioration and adverse outcomes in patients with acute ischemic stroke treated with intravenous thrombolysis (IVT) therapy. Although current guidelines recommend delaying antithrombotic therapy until 24 h after IVT to reduce hemorrhagic risks, the persistently high incidence of reocclusion has prompted the exploration of earlier antithrombotic strategies. Despite theoretical benefits, extensive research has not consistently demonstrated the efficacy of early antithrombotic interventions. Nevertheless, a recent randomized controlled trial encouragingly demonstrated that ultra-early intravenous administration of the antiplatelet agent tirofiban after IVT was effective at improving functional outcomes in non-cardioembolic stroke patients with a low risk of hemorrhage. However, the considerable heterogeneity in both antithrombotic regimens and patient populations across existing studies has obscured the identification of beneficial candidates and intervention protocols for early post-thrombolysis antithrombotic therapy. We synthesizes the current evidence regarding patient selection, drug choice, and optimal timing for early antithrombotic therapy, to explore potential improvements in post-IVT antithrombotic management, emphasizing the critical need to balance the prevention of ischemic progression with the risk of hemorrhagic transformation.
- 20 January 2026
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 26 (2) , 233-241
Impact of Prestroke Antiplatelet Therapy on the Efficacy of Intravenous Tirofiban at Preventing Early Neurological Deterioration: A Prespecified Subgroup Analysis of the TREND Trial
Background Early neurological deterioration (END) in patients with acute ischemic stroke (AIS) is a common phenomenon strongly associated with unfavorable outcomes. The TREND trial (NCT04491695) demonstrates the efficacy of intravenous tirofiban compared to oral aspirin in preventing END. Aims The purpose of this study was to explore whether prior antiplatelet therapy (APT) affected the therapeutic effects of tirofiban. Methods This prespecified post hoc analysis of the TREND trial stratified patients by prior antiplatelet use. The primary outcome was END4 (≥ 4 points increase in National Institutes of Health Stroke Scale [NIHSS] within 72 h). Secondary outcomes included END2 (≥ 2 points increase in NIHSS), early neurological improvement, 90-day functional outcomes, and safety events. Results Overall, 425 patients with AIS were analyzed, including 143 (33.6%) and 282 (66.4%) with and without prior APT, respectively. In patients without prior APT, tirofiban significantly reduced the risk of END4 compared with aspirin (5.0% versus 14.2%; adjusted OR, 0.38; 95% CI 0.15–0.96; P = 0.040). Tirofiban was beneficial in reducing the risk of END₂ in both patients with (8.3% versus 22.5%, P = 0.020) or without prior APT (13.5% versus 24.1%; P = 0.032). There was no significant interaction between treatment and prior APT status (P for interaction > 0.05). Further, no significant differences in 90-day functional outcomes or safety events were observed between the treatment groups for either antiplatelet status after adjustment. Conclusions Intravenous tirofiban significantly reduced the risk of END compared with aspirin in patients with AIS who were not on prestroke APT. Although this benefit was attenuated in pretreated patients, tirofiban might maintain a consistent efficacy and safety profile irrespective of prior antiplatelet use.
- 20 January 2026
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 26 (2) , 233-241
Impact of Prestroke Antiplatelet Therapy on the Efficacy of Intravenous Tirofiban at Preventing Early Neurological Deterioration: A Prespecified Subgroup Analysis of the TREND Trial
Background Early neurological deterioration (END) in patients with acute ischemic stroke (AIS) is a common phenomenon strongly associated with unfavorable outcomes. The TREND trial (NCT04491695) demonstrates the efficacy of intravenous tirofiban compared to oral aspirin in preventing END. Aims The purpose of this study was to explore whether prior antiplatelet therapy (APT) affected the therapeutic effects of tirofiban. Methods This prespecified post hoc analysis of the TREND trial stratified patients by prior antiplatelet use. The primary outcome was END4 (≥ 4 points increase in National Institutes of Health Stroke Scale [NIHSS] within 72 h). Secondary outcomes included END2 (≥ 2 points increase in NIHSS), early neurological improvement, 90-day functional outcomes, and safety events. Results Overall, 425 patients with AIS were analyzed, including 143 (33.6%) and 282 (66.4%) with and without prior APT, respectively. In patients without prior APT, tirofiban significantly reduced the risk of END4 compared with aspirin (5.0% versus 14.2%; adjusted OR, 0.38; 95% CI 0.15–0.96; P = 0.040). Tirofiban was beneficial in reducing the risk of END₂ in both patients with (8.3% versus 22.5%, P = 0.020) or without prior APT (13.5% versus 24.1%; P = 0.032). There was no significant interaction between treatment and prior APT status (P for interaction > 0.05). Further, no significant differences in 90-day functional outcomes or safety events were observed between the treatment groups for either antiplatelet status after adjustment. Conclusions Intravenous tirofiban significantly reduced the risk of END compared with aspirin in patients with AIS who were not on prestroke APT. Although this benefit was attenuated in pretreated patients, tirofiban might maintain a consistent efficacy and safety profile irrespective of prior antiplatelet use.
- Open Access
- 26 November 2018
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 15 (1) , 1-8
Inflammation is correlated with severity and outcome of cerebral venous thrombosis
Few studies have suggested a relationship between inflammation and cerebral venous thrombosis (CVT). This retrospective study aimed to explore the changes in inflammation in different CVT stages and the correlation between inflammation and severity and outcome of CVT. In total, 95 suitable patients with CVT and 41 controls were compared. Patients with CVT were divided into three groups. The inflammatory factors studied included hypersensitive C-reactive protein (Hs-CRP), interleukin-6 (IL-6), and neutrophil-to-lymphocyte ratio (NLR) in the peripheral blood and immunoglobulin A (IgA), immunoglobulin M (IgM), and immunoglobulin G (IgG) in the cerebrospinal fluid (CSF). The severity of CVT was evaluated with the modified Rankin Scale (mRS), the National Institutes of Health Stroke Scale (NIHSS), fundus condition, intracranial pressure (ICP), and complications on admission. The short-term outcome was evaluated with the mRS at discharge. The following results were obtained: (1) Inflammatory factor levels in patients with CVT were higher than those in the controls. (2) Inflammatory factor levels in the acute and subacute stages were significantly higher than those in the chronic stage (all P < 0.05). (3) Serum NLR and CSF IgM levels were positively related to baseline degree of disability (odds ratio [OR], 1.279, 95% confidence interval [CI] 1.009–1.621, P = 0.042; OR 1.402, 95% CI 1.036–1.896, P = 0.028). The Hs-CRP level was positively correlated with the baseline occurrence of seizure (OR 1.040, 95% CI 1.001–1.080, P = 0.043). The baseline serum NLR (r = 0.244, P = 0.017), CSF IgA (r = 0.615, P < 0.001), CSF IgM (r = 0.752, P < 0.001), and CSF IgG (r = 0.248, P = 0.015) levels were positively associated with NIHSS. (4) The baseline NLR was significantly associated with high risk of poor outcome at discharge (OR 1.339, 95% CI 1.097–1.784, P = 0.007). Moreover, the ROC showed that NLR ≥ 4.205 could better predict the poor outcome at discharge. The data were analyzed using SPSS. Inflammation may develop after CVT and gradually decrease during the course. Inflammation was significantly correlated with severity on admission and short-term poor outcome at discharge in CVT.
- 26 November 2018
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 15 (1) , 1-8
Open AccessInflammation is correlated with severity and outcome of cerebral venous thrombosis
Few studies have suggested a relationship between inflammation and cerebral venous thrombosis (CVT). This retrospective study aimed to explore the changes in inflammation in different CVT stages and the correlation between inflammation and severity and outcome of CVT. In total, 95 suitable patients with CVT and 41 controls were compared. Patients with CVT were divided into three groups. The inflammatory factors studied included hypersensitive C-reactive protein (Hs-CRP), interleukin-6 (IL-6), and neutrophil-to-lymphocyte ratio (NLR) in the peripheral blood and immunoglobulin A (IgA), immunoglobulin M (IgM), and immunoglobulin G (IgG) in the cerebrospinal fluid (CSF). The severity of CVT was evaluated with the modified Rankin Scale (mRS), the National Institutes of Health Stroke Scale (NIHSS), fundus condition, intracranial pressure (ICP), and complications on admission. The short-term outcome was evaluated with the mRS at discharge. The following results were obtained: (1) Inflammatory factor levels in patients with CVT were higher than those in the controls. (2) Inflammatory factor levels in the acute and subacute stages were significantly higher than those in the chronic stage (all P < 0.05). (3) Serum NLR and CSF IgM levels were positively related to baseline degree of disability (odds ratio [OR], 1.279, 95% confidence interval [CI] 1.009–1.621, P = 0.042; OR 1.402, 95% CI 1.036–1.896, P = 0.028). The Hs-CRP level was positively correlated with the baseline occurrence of seizure (OR 1.040, 95% CI 1.001–1.080, P = 0.043). The baseline serum NLR (r = 0.244, P = 0.017), CSF IgA (r = 0.615, P < 0.001), CSF IgM (r = 0.752, P < 0.001), and CSF IgG (r = 0.248, P = 0.015) levels were positively associated with NIHSS. (4) The baseline NLR was significantly associated with high risk of poor outcome at discharge (OR 1.339, 95% CI 1.097–1.784, P = 0.007). Moreover, the ROC showed that NLR ≥ 4.205 could better predict the poor outcome at discharge. The data were analyzed using SPSS. Inflammation may develop after CVT and gradually decrease during the course. Inflammation was significantly correlated with severity on admission and short-term poor outcome at discharge in CVT.